Combined treatment with Ad-hTRAIL and DTIC or SAHA is associated with increased mitochondrial-mediated apoptosis in human melanoma cell lines

Journal of Gene Medicine

Volumn 9, Issue 6, 2007, Pages 440-451

  Lillehammer, Trine ^a   Engesaeter, Birgit O ^a   Prasmickaite, Lina ^a   Maelandsmo, Gunhild M ^a   Fodstad, Oystein ^a,b   Engebraaten, Olav ^a,b  

^a OSLO UNIVERSITY HOSPITAL   (Norway)

^b UNIVERSITY OF OSLO   (Norway)

Author keywords

Apoptosis; Dacarbazine; Full length TRAIL; Gene therapy; Histone deacetylase inhibitor; Human melanoma

Indexed keywords

ADENOVIRUS VECTOR; CASPASE; CASPASE 8; DACARBAZINE; DEATH RECEPTOR; DEATH RECEPTOR 4; DEATH RECEPTOR 5; PROCASPASE 3; PROCASPASE 8; PROCASPASE 9; PROTEIN BCL 2; PROTEIN BCL XL; PROTEIN BID; PROTEIN MCL 1; TUMOR NECROSIS FACTOR RELATED APOPTOSIS INDUCING LIGAND; VORINOSTAT; X LINKED INHIBITOR OF APOPTOSIS;

APOPTOSIS; ARTICLE; CANCER CELL CULTURE; CELL VIABILITY; COMBINATION CHEMOTHERAPY; CONTROLLED STUDY; CYTOTOXICITY; DOWN REGULATION; DRUG POTENTIATION; DRUG RESEARCH; ENZYME ACTIVATION; GROWTH INHIBITION; HUMAN; HUMAN CELL; MELANOMA; MEMBRANE POTENTIAL; MITOCHONDRIAL MEMBRANE; MITOCHONDRION; MONOTHERAPY; NICK END LABELING; PRIORITY JOURNAL; PROTEIN DEGRADATION; PROTEIN EXPRESSION; TREATMENT OUTCOME; VIRAL GENE DELIVERY SYSTEM;

ADENOVIRIDAE; ANTINEOPLASTIC AGENTS; APOPTOSIS; BCL-X PROTEIN; BH3 INTERACTING DOMAIN DEATH AGONIST PROTEIN; CASPASES; CELL LINE, TUMOR; CELL SURVIVAL; DACARBAZINE; DOWN-REGULATION; DRUG SYNERGISM; HUMANS; HYDROXAMIC ACIDS; MELANOMA; MEMBRANE POTENTIAL, MITOCHONDRIAL; MITOCHONDRIA; NEOPLASM PROTEINS; PROTO-ONCOGENE PROTEINS C-BCL-2; TNF-RELATED APOPTOSIS-INDUCING LIGAND; TRANSDUCTION, GENETIC; X-LINKED INHIBITOR OF APOPTOSIS PROTEIN;

EID: 34347226747     PISSN: 1099498X     EISSN: 15212254     Source Type: Journal    
DOI: 10.1002/jgm.1036     Document Type: Article

References (56)

1. Eggermont AM, Kirkwood JM. Re-evaluating the role of dacarbazine in metastatic melanoma: What have we learned in 30 years? Eur J Cancer 2004; 40: 1825-1836.
2. Huncharek M, Caubet JF, McGarry R. Single-agent DTIC versus combination chemotherapy with or without immunotherapy in metastatic melanoma: A meta-analysis of 3273 patients from 20 randomized trials. Melanoma Res 2001; 11: 75-81.
3. Tarhini AA, Agarwala SS. Cutaneous melanoma: Available therapy for metastatic disease. Dermatol Ther 2006; 19: 19-25.
4. Ashkenazi A. Targeting death and decoy receptors of the tumour-necrosis factor superfamily. Nat Rev Cancer 2002; 2: 420-430.
5. Griffith TS, Chin WA, Jackson GC, et al. Intracellular regulation of TRAIL-induced apoptosis in human melanoma cells. J Immunol 1998; 161: 2833-2840.
6. Wang S, El-Deiry WS. TRAIL and apoptosis induction by TNF-family death receptors. Oncogene 2003; 22: 8628-8633.
7. Eskes R, Desagher S, Antonsson B, et al. Bid induces the oligomerization and insertion of Bax into the outer mitochondrial membrane. Mol Cell Biol 2000; 20: 929-935.
8. Zhuang L, Lee CS, Scolyer RA, et al. Progression in melanoma is associated with decreased expression of death receptors for tumor necrosis factor-related apoptosis-inducing ligand. Hum Pathol 2006; 37: 1286-1294.
9. McCarthy MM, DiVito KA, Sznol M, et al. Expression of tumor necrosis factor-related apoptosis-inducing ligand receptors 1 and 2 in melanoma. Clin Cancer Res 2006; 12: 3856-3863.
10. Thomas WD, Hersey P. TNF-related apoptosis-inducing ligand (TRAIL) induces apoptosis in Fas ligand-resistant melanoma cells and mediates CD4 T cell killing of target cells. J Immunol 1998; 161: 2195-2200.
11. Kelley SK, Harris LA, Xie D, et al. Preclinical studies to predict the disposition of Apo2L/tumor necrosis factor-related apoptosis-inducing ligand in humans: Characterization of in vivo efficacy, pharmacokinetics, and safety. J Pharmacol Exp Ther 2001; 299: 31-38.
12. Yagita H, Takeda K, Hayakawa Y, et al. TRAIL and its receptors as targets for cancer therapy. Cancer Sci 2004; 95: 777-783.
13. Lee J, Hampl M, Albert P, et al. Antitumor activity and prolonged expression from a TRAIL-expressing adenoviral vector. Neoplasia 2002; 4: 312-323.
14. Lin T, Huang X, Gu J, et al. Long-term tumor-free survival from treatment with the GFP-TRAIL fusion gene expressed from the hTERT promoter in breast cancer cells. Oncogene 2002; 21: 8020-8028.
15. Zhang L, Fang B. Mechanisms of resistance to TRAIL-induced apoptosis in cancer. Cancer Gene Ther 2005; 12: 228-237.
16. Kurbanov BM, Fecker LF, Geilen CC, et al. Resistance of melanoma cells to TRAIL does not result from upregulation of antiapoptotic proteins by NF-kappaB but is related to downregulation of initiator caspases and DR4. Oncogene 2006; Dec 11 [Epub ahead of print].
17. Zhang XD, Zhang XY, Gray CP, et al. Tumor necrosis factor-related apoptosis-inducing ligand-induced apoptosis of human melanoma is regulated by smac/DIABLO release from mitochondria. Cancer Res 2001; 61: 7339-7348.
18. Franco AV, Zhang XD, Van Berkel E, et al. The role of NF-kappa B in TNF-related apoptosis-inducing ligand (TRAIL)-induced apoptosis of melanoma cells. J Immunol 2001; 166: 5337-5345.
19. Ivanov VN, Hei TK. Sodium arsenite accelerates TRAIL-mediated apoptosis in melanoma cells through upregulation of TRAIL-R1/R2 surface levels and downregulation of cFLIP expression. Exp Cell Res 2006; 312: 4120-4138.
20. Hussein MR, Haemel AK, Wood GS. Apoptosis and melanoma: Molecular mechanisms. J Pathol 2003; 199: 275-288.
21. Hersey P. Apoptosis and melanoma: How new insights are effecting the development of new therapies for melanoma. Curr Opin Oncol 2006; 18]: 189-196.
22. Sanlioglu AD, Dirice E, Aydin C, et al. Surface TRAIL decoy receptor-4 expression is correlated with TRAIL resistance in MCF7 breast cancer cells. BMC Cancer 2005; 5: 54.
23. Aydin C, Sanlioglu AD, Karacay B, et al. Decoy receptor-2 small interfering RNA (siRNA) strategy employing three different siRNA constructs in combination defeats adenovirus-transferred tumor necrosis factor-related apoptosis-inducing ligand resistance in lung cancer cells. Hum Gene Ther 2007; 18: 39-50.
24. Qiu L, Kelso MJ, Hansen C, et al. Anti-tumour activity in vitro and in vivo of selective differentiating agents containing hydroxamate. Br J Cancer 1999; 80: 1252-1258.
25. Boyle GM, Martyn AC, Parsons PG. Histone deacetylase inhibitors and malignant melanoma. Pigment Cell Res 2005; 18: 160-166.
26. Zhang XD, Gillespie SK, Borrow JM, et al. The histone deacetylase inhibitor suberic bishydroxamate regulates the expression of multiple apoptotic mediators and induces mitochondria-dependent apoptosis of melanoma cells. Mol Cancer Ther 2004; 3: 425-435.
27. Bolden JE, Peart MJ, Johnstone RW. Anticancer activities of histone deacetylase inhibitors. Nat Rev Drug Discov 2006; 5: 769-784.
28. Nakata S, Yoshida T, Horinaka M, et al. Histone deacetylase inhibitors upregulate death receptor 5/TRAIL-R2 and sensitize apoptosis induced by TRAIL/APO2-L in human malignant tumor cells. Oncogene 2004; 23: 6261-6271.
29. Vanoosten RL, Earel JK, Griffith TS. Enhancement of Ad5-TRAIL cytotoxicity against renal cell carcinoma with histone deacetylase inhibitors. Cancer Gene Ther 2006; 1-5.
30. El-Zawahry A, Lu P, White SJ, et al. In vitro efficacy of AdTRAIL gene therapy of bladder cancer is enhanced by trichostatin A-mediated restoration of CAR expression and downregulation of cFLIP and Bcl-XL. Cancer Gene Ther 2006; 13]: 281-289.
31. Lin T, ZhangL, Davis J, et al. Combination of TRAIL gene therapy and chemotherapy enhances antitumor and antimetastasis effects in chemosensitive and chemoresistant breast cancers. Mol Ther 2003; 8: 441-448.
32. Fodstad O, Kjonniksen I, AAmdal S, et al. Extrapulmonary, tissue-specific metastasis formation in nude mice injected with FEMX-I human melanoma cells. Cancer Res 1988; 48: 4382-4388.
33. Fodstad O, Aamdal S, McMenamin M, et al. A new experimental metastasis model in athymic nude mice, the human malignant melanoma LOX. Int J Cancer 1988; 41: 442-449.
34. Li D, Duan L, Freimuth P, et al. Variability of adenovirus receptor density influences gene transfer efficiency and therapeutic response in head and neck cancer. Clin Cancer Res 1999; 5: 4175-4181.
35. Du L, Lyle CS, Chambers TC. Characterization of vinblastine-induced Bcl-xL and Bcl-2 phosphorylation: Evidence for a novel protein kinase and a coordinated phosphorylation/dephosphorylation cycle associated with apoptosis induction. Oncogene 2005; 24: 107-117.
36. Thomas WD, Zhang XD, Franco AV, et al. TNF-related apoptosis-inducing ligand-induced apoptosis of melanoma is associated with changes in mitochondrial membrane potential and perinuclear clustering of mitochondria. J Immunol 2000; 165: 5612-5620.
37. Ruefli AA, Ausserlechner MJ, Bernhard D, et al. The histone deacetylase inhibitor and chemotherapeutic agent suberoylanilide hydroxamic acid (SAHA) induces a cell-death pathway characterized by cleavage of Bid and production of reactive oxygen species. Proc Natl Acad Sci USA 2001; 98: 10833-10838.
38. Richon VM, Sandhoff TW, Rifkind RA, et al. Histone deacetylase inhibitor selectively induces p21WAF1 expression and gene-associated histone acetylation. Proc Natl Acad Sci U S A 2000; 97: 10014-10019.
39. Burgess AJ, Pavey S, Warrener R, et al. Up-regulation of p21 (WAF1/CIP1) by histone deacetylase inhibitors reduces their cytotoxicity. Mol Pharmacol 2001; 60: 828-837.
40. Broker LE, Kruyt FA, Giaccone G. Cell death independent of caspases: A review. Clin Cancer Res 2005; 11: 3155-3162.
41. Srivastava RK. TRAIL/Apo-2L: Mechanisms and clinical applications in cancer. Neoplasia 2001; 3: 535-546.
42. Facchetti F, Previdi S, Ballarini M, et al. Modulation of pro- and anti-apoptotic factors in human melanoma cells exposed to histone deacetylase inhibitors. Apoptosis 2004; 9: 573-582.
43. Choi KH, Basma H, Singh J, et al. Activation of CMV promoter-controlled glycosyltransferase and beta-galactosidase glycogenes by butyrate, tricostatin A, and 5-aza-2′-deoxycytidine. Glycoconjugate J 2005; 22: 63-69.
44. Kurbanov BM, Geilen CC, Fecker LF, et al. Efficient TRAIL-R1/ DR4-mediated apoptosis in melanoma cells by tumor necrosis factor-related apoptosis-inducing ligand (TRAIL). J Invest Dermatol 2005; 125: 1010-1019.
45. Gillespie S, Borrow J, Zhang XD, et al. Bim plays a crucial role in synergistic induction of apoptosis by the histone deacetylase inhibitor SBHA and TRAIL in melanoma cells. Apoptosis 2006; 11 2251-2265.
46. Haskell GM. Cancer Treatment, WB Saunders & Co: Philadelphia, 1990.
47. Chabner BA, Myers CE. Cancer: Principles and Practice of Oncology, JB Lippincott & Co: Philadelphia, 1989.
48. Loo TL, Housholder GE, Gerulath AH, et al. Mechanism of action and pharmacology studies with DTIC (NSC-45388). Cancer Treat Rep 1976; 60: 149-152.
49. Fuggetta MP, D'Atri S, Lanzilli G, et al. In vitro antitumour activity of resveratrol in human melanoma cells sensitive or resistant to temozolomide. Melanoma Res 2004; 14: 189-196.
50. Nagane M, Pan G, Weddle JJ, et al. Increased death receptor 5 expression by chemotherapeutic agents in human gliomas causes synergistic cytotoxicity with tumor necrosis factor-related apoptosis-inducing ligand in vitro and in vivo. Cancer Res 2000; 60: 847-853.
51. Gibson SB, Oyer R, Spalding AC, et al. Increased expression of death receptors 4 and 5 synergizes the apoptosis response to combined treatment with etoposide and TRAIL. Mol Cell Biol 2000; 20: 205-212.
52. Tentori L, Graziani G. Correspondence re: DC Lev, et al., Dacarbazine causes transcriptional up-regulation of interleukin 8 and vascular endothelial growth factor in melanoma cells: A possible escape mechanism from chemotherapy. Mol Cancer Ther, 2003; 2: 753-763; Mol Cancer Ther 2004; 3: 383; author reply 383-384.
53. Shibuya H, Kato Y, Saito M, et al. Induction of apoptosis and/or necrosis following exposure to antitumour agents in a melanoma cell line, probably through modulation of Bcl-2 family proteins. Melanoma Res 2003; 13: 457-464.
54. Olszewska-Slonina DM, Styczynisk J, Drewa TA, et al. B16 and cloudman S91 mouse melanoma cells susceptibility to apoptosis after dacarbazine treatment. Acta Pol Pharm 2005; 62: 473-483.
55. Ichikawa K, Liu W, Zhao L, et al. Tumoricidal activity of a novel anti-human DR5 monoclonal antibody without hepatocyte cytotoxicity. Nat Med 2001; 7: 954-960.
56. Abou El Hassan MA, Mastenbroek DC, Gerritsen WR, et al. Overexpression of Bcl2 abrogates chemo- and radiotherapy-induced sensitisation of NCl-H460 non-small-cell lung cancer cells to adenovirus-mediated expression of full-length TRAIL. Br J Cancer 2004; 91: 171-177.